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The RNA-guided CRISPR/Cas9 tool kit 
(clustered regularly interspaced short pal-
indromic repeats/CRISPR associated pro-
tein 9) for genome engineering is being 
widely used, for various applications from 
basic research to the development of novel 
therapeutics.[1] While the genome editing 
tool holds tremendous promise for bio-
medical applications, the unstable and 
large size of the CRISPR/Cas9 system 
have been one of the major challenges 
of its effective intracellular delivery.[2] 
Additionally, the target specificity of the 
CRISPR/Cas9 system has also been a 
critical issue.[2a,3] For permanently modi-
fying genomic DNA using genome editing 
techniques, the specific and one-time 
effect is of utmost importance. Previously, 
genes encoding the CRISPR/Cas9 compo-
nents, namely, the Cas9 protein and guide 
A transient cytosolic delivery system for accurate Cas9 ribonucleoprotein 
is a key factor for target specificity of the CRIPSR/Cas9 toolkit. Owing to 
the large size of the Cas9 protein and a long negative strand RNA, the 
development of the delivery system is still a major challenge. Here, a size-
controlled lipopeptide-based nanosome system is reported, derived from the 
blood-brain barrier-permeable dNP2 peptide which is capable of delivering 
a hyperaccurate Cas9 ribonucleoprotein complex (HypaRNP) into human 
cells for gene editing. Each nanosome is capable of encapsulating and 
delivering ≈2 HypaRNP molecules into the cytoplasm, followed by nuclear 
localization at 4 h post-treatment without significant cytotoxicity. The 
HypaRNP thus efficiently enacts endogenous eGFP silencing and editing in 
human embryonic kidney cells (up to 27.6%) and glioblastoma (up to 19.7% 
frequency of modification). The lipopeptide-based nanosome system shows 
superior delivery efficiency, high controllability, and simplicity, thus providing 
biocompatibility and versatile platform approach for CRISPR-mediated 
transient gene editing applications.
Dr. T. T. Thach, N. H. Kim, E. S. Kang, Dr. B. S. Lee,  
Dr. M. Kwak, H. J. Choi, J. Nam, Prof. Y. H. Kim
SKKU Advanced Institute of Nanotechnology (SAINT)
Sungkyunkwan University
South Suwon 16419, Korea
E-mail: yhkim94@skku.edu
D. H. Bae, Prof. Y. H. Kim
Department of Biomedical Engineering
Sungkyunkwan University
Suwon 16419, South Korea
K. Han, Prof. M. Suh
Center for Neuroscience Imaging Research (CNIR)
Institute for Basic Science (IBS)
Sungkyunkwan University





Seoul 02447, South Korea
Prof. M. Suh
Department of Nano Engineering
Sungkyunkwan University
Suwon 16419, South Korea




Seoul 02447, South Korea
Prof. J. K. Hur
Department of Biomedical Science
Graduate School
Kyung Hee University
Seoul 02447, South Korea
Prof. Y. H. Kim
Biomedical Institute for Convergence at SKKU (BICS)
Sungkyunkwan University
Suwon 16419, South Korea
The ORCID identification number(s) for the author(s) of this article 
can be found under https://doi.org/10.1002/smll.201903172.
Small 2019, 15, 1903172
1903172 (2 of 8)
www.advancedsciencenews.com
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.small-journal.com
RNA from Streptococcus pyogenes (SpCas9), were delivered via 
plasmids using either lipofectamine or by viral vectors, which 
prolonged their expression, thus raising off-target effects and 
toxicity.[2b,4] To minimize the off-target effects, one of the more 
straightforward approaches is the delivery of the Cas9:sgRNA 
ribonucleoprotein complex (RNP) in vitro and in vivo.[3b] This 
approach directly delivers high levels of the genome editing 
RNP machinery that functions immediately without transcrip-
tion and translation. Moreover, the RNP complex is transient 
which means that it is rapidly cleared in cells, resulting in a 
“fast on, fast off” mode with high efficiency, specificity, and low 
toxicity compared to the strategies involving viral delivery of 
genes coding Cas9:sgRNA.[2b,5] The delivery of RNP using cati-
onic lipid-induced genomic modification with approximately 
tenfold higher specificity compared to plasmid transfection.[5b] 
However, as the widely used SpCas9 is a large multidomain 
protein (1368 aa, ≈10 nm diameter) with a high positive charge 
and a long negative strand of sgRNA,[6] several aspects of devel-
oping effective delivery systems for RNPs remain a challenge 
that is continuously being tackled. The application of gold 
nanoparticles,[5a,7] black phosphorus nanosheets,[8] or metal-
coordination frameworks[9] have demonstrated their utility as 
efficient RNP delivery platforms. However, the aforementioned 
systems are limited by large size (over 100 nm), low levels of 
endosomal escape, usage of nonbiodegradable materials and 
metals that results in prevention of intracellular uptake and 
RNP release, and incensement of toxicity problems.
Lipopeptides are amphiphilic molecules that can self-
assemble to form peptide-functionalized nanostructures. 
Lipopeptide-based nanoparticles are well-suited for intracel-
lular delivery of macromolecules, which are encapsulated in 
the solvent-filled cavity.[10] To further improve the delivery effi-
ciency, they can be modified to target cellular membrane by 
introducing appropriate components. Here, we developed a 
size-controlled delivery system derived from dNP2 lipopeptide, 
hereafter called nanosome. dNP2 is a tandem repeat of the 
blood-brain barrier-permeable peptide (KIKKVKKKGRK), which 
is highly efficient in in vitro and in vivo deliveries, including 
to brain tissue without significant toxicity.[11] The intracellular 
delivery of dNP2 mainly utilizes lipid raft-mediated endocytosis 
upon heparan sulfate interaction, resulting in highly efficient 
delivery and endosomal escape in the cytosol.[11a,12]
As previous report showed that the hyperaccurate SpCas9 
(HypaCas9) variant efficiently and specifically mediated gene 
editing better than WT protein by reducing the relative affinity 
to the target DNA,[13] we performed site-direct mutagenesis 
to obtain a HypaCas9 variant with seven point-mutations 
(K848A, K1003A, R1060A, N497A, R661A, Q695A, and Q926A) 
in SpCas9 WT (Figure 1a and Figure S1, Supporting Infor-
mation). To use HypaCas9 for gene editing in mammalian 
cells, we further inserted the SV40 nuclear localization signal 
(NLS, PKKKRKV) at the C-terminus with flexible GGS linker 
to enrich in mammalian cell nuclei (Figure 1a). Successful 
overexpression and purification of Cas9 via the recombinant 
His-MBP tag were confirmed using fast protein liquid chro-
matography (FPLC) and sodium dodecyl sulfate (SDS)-PAGE 
(Figure S2a–d, Supporting Information). Furthermore, to mon-
itor HypaCas9:sgRNA ribonucleoprotein complex (HypaRNP) 
localization, we labeled HypaCas9 with Cy3 maleimide via 
two solvent-exposed cysteine residues on the protein (C80 and 
C574) (Figure S2c,d, Supporting Information). Cy3-labeled 
HypaCas9 did not hamper the protein folding and the nuclease 
activity compared to free HypaCas9 as was evident from the 
results of circular dichroism and DNA cleavage assay, respec-
tively (Figure S2e,f, Supporting Information). The results 
showed that our labeled protein is suitable for use similar to 
free protein. Our key goal was to generate size-controlled lipo-
peptide-based nanosomes derived from dNP2 with a cavity suit-
able to encapsulate and directly deliver HypaRNP into human 
cells for gene editing. Towards this purpose, we first chemi-
cally synthesized a blood-brain barrier-permeable dNP2 pep-
tide using the solid-phase peptide chemistry. To generate dNP2 
lipopeptide variants, we next conjugated the peptide to different 
types of saturated fatty acids including caprylic or octanoic 
acid (C8:0), capric or decanoic acid (C10:0), and myristic or 
tetradecanoic acid (C14:0) through a peptide bond. Successful 
synthesis and purification of the lipopeptides were confirmed 
using reverse-phase high-performance liquid chromatography 
(HPLC), followed by matrix-assisted laser desorption/ioniza-
tion-time-of-flight (MALDI-TOF) analysis (Figure S3a–c, Sup-
porting Information). Analyses of the final products showed 
the corrected molecular mass for each lipopeptide with purity 
level over 95% (Figure S3a–c, Supporting Information). To 
check the capacity of the nanosomes formed from the designed 
dNP2 lipopeptides for further cell-treatment, we examined the 
hydrodynamic diameters of these lipopeptide-based nanosomes 
using dynamic light scattering (DLS). The analysis showed that 
at a lipopeptide concentration of 50 × 10−6 m, the diameters of 
the C8dNP2 and C10dNP2 nanosomes were ≈27.2 and ≈30 nm, 
respectively; the longer lipopeptide, C14dNP2, was over 500 nm 
(Figure S4a and Table S2, Supporting Information). Consist-
ently, the further transmission electron microscopy (TEM) anal-
ysis revealed that the C14dNP2 lipopeptide was aggregated or 
unable to form nanosomes, whereas C8dNP2 was able to form 
homologous nanosomes better than the C10dNP2 (Figure S4b, 
Supporting Information). Alternatively, the 3D structure and 
length of the free dNP2 lipopeptide were theoretically mod-
eled and calculated using Phyre[14] and PyMol,[15] respectively. 
The length of the free C8dNP2 lipopeptide was estimated to 
be ≈2.8 nm, suggesting that the lipopeptide-based nanosomes 
have a capacity to encapsulate HypaRNP, which is ≈10 nm of 
size (Figure 1b–d and Figure S1, Supporting Information). 
Therefore, we selected C8dNP2-based nanosomes for HypaRNP 
encapsulation experiments. To investigate the HypaRNP encap-
sulation condition using the C8dNP2-based nanosomes with 
minimal lipopeptide concentration, we purified the RNP com-
plex using a size exclusion column (Figure S2a–d, Supporting 
Information) and then encapsulated 0.5 × 10−6 m of RNP in 
nanosomes using different C8dNP2 lipopeptide concentra-
tions. The hydrodynamic diameter assessed using DLS indi-
cated that the diameter of HypaRNP was ≈10.0 nm (Table S2, 
Supporting Information), which is consistent with the size pre-
dicted from the atomic structure (Figure S1, Supporting Infor-
mation) and TEM data (Figure S4c, Supporting Information). 
The RNP might not stably be encapsulated in the nanosomes 
formed by 12.5 × 10−6 m C8dNP2 (ratio 25:1) with the low and 
broad size distribution (Figure 2a). We hypothesized that the 
25:1 molar ratio of the lipopeptide to RNP is not enough for 
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nanosome proportion to encapsulate the RNP. Hence, we next 
examined the 50:1 and 100:1 ratio with nanosome concentra-
tions of 25 and 50 × 10−6 m, respectively. DLS data showed 
the diameter of the C8dNP2/RNP ratio of (50:1) and (100:1) 
were ≈35.2 and ≈40.5 nm, respectively; which is considered a 
potential condition for complete encapsulation of HypaRNP 
by the C8dNP2-based nanosomes (Figure 2a, Table S2, Sup-
porting Information). Measuring zeta potential showed that 
the positively charged HypaRNP-encapsulated nanosomes 
were 37.1 ± 7.8 mV compared to 33.6 ± 6.9 mV of the free 
nanosomes and 0.5 ± 5.3 mV of HypaRNP indicating that the 
positive nanosome system would facilitate the intracellular 
delivery of HypaRNP (Table S2, Supporting Information). Fur-
ther TEM data also consistently showed the highly homolo-
gous morphology of the RNP-encapsulated nanosomes in the 
50:1 ratio with the size of ≈35 nm (Figure 2b). To minimize 
the amount of lipopeptide usage, we selected 25 × 10−6 m of 
C8dNP2-based nanosomes for further experiments. UV–visible 
spectrophotometric data indicated that the Cy3 fluorescence 
decreased significantly by 64 ± 12% in the encapsulated RNP-
based nanosomes for 4 h at least, but not in the unencapsu-
lated mixture (free Cy3RNP and lipopeptide), indicating that 
Small 2019, 15, 1903172
Figure 1. Schematic illustration displaying the formation and intracellular delivery of HypaCas9 RNP-encapsulated nanosome for gene editing. 
a) HypaCas9-NLS engineering. Residue numbers for the boundaries of domains and the construct are displayed. Residues mutated in this study are 
indicated by filled triangles. b) Structure model of dNP2 lipopeptide and fatty acid. c,d) Encapsulating the HypaCas9 RNP within dNP2 lipopeptide-
based nanosomes. The blood-brain barrier-permeable dNP2 peptide may facilitate direct transcytosis and release of the HypaRNP for gene editing in 
human cells. NLS, SV40 nuclear localization signal peptide.
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the HypaRNP is stably encapsulated within the C8dNP2-based 
nanosome (Figure 2c and Figure S5, Supporting Information). 
The encapsulation was validated by lysing of the nanosomes 
using protease K, in which the Cy3 intensity was recovered 
similarly to the unencapsulated ones (Figure 2c). Importantly, 
the CD data showed a similar ratio of the secondary structure 
of the RNP without and with the nanosome encapsulation 
(Figure 2d and Table S3, Supporting Information), suggesting 
the C8dNP2-based nanosome system did not disrupt the RNP 
structure. Together, these data suggested that HypaRNP is suit-
ably encapsulated in the lipopeptide-based nanosome system 
without loss of Cas9 nuclease activity. We further explored 
the shape and molecular mass of C8dNP2-based nanosome 
system in aqueous phase using small-angle X-ray scattering 
(SAXS) measurements. In the small-angle region of the scat-
tering vector q < 0.1 Å−1, the experimental scattering profile fol-
lowed the q−1 power law, corresponding to the globular shape 
(Figure 2e). The pair distribution functions, (P(r)), displayed a 
bell-shape, indicating a characteristic of the globular shape with 
a maximum interatomic distance, Dmax of 11.9 nm (HypaRNP), 
28.7 nm (nanosome) and 39.1 nm (RNP-encapsulated nano-
some) (Figure 2f and Table S4, Supporting Information). The 
radius of gyration Rg determined from Guinier plots was in 
good agreement with that from P(r), supporting the monodis-
perse state of the sample during SAXS measurements (Table S4, 
Supporting Information). The molecular mass of the RNP, 
nanosome, or RNP-nanosome was calculated via the abso-
lute scattering intensity using bovine serum albumin (BSA) 
Figure 2. The HypaCas9 RNP-encapsulated nanosome. a) Distribution of hydrodynamic diameter of HypaRNP-encapsulated C8dNP2-nanosomes 
(HypaRNP-nanosome). A constant amount of RNP was encapsulated by C8dNP2-based nanosomes with various molar ratios. b) Representative 
TEM images of RNP-encapsulated C8dNP2-based nanosomes. Scale bar, 20 nm. c) UV–visible spectra showing the encapsulation of Cy3-RNP within 
C8dNP2-based nanosomes. Cy3 absorbance signal is significantly decreased in the encapsulated RNP, but recovered after lysis compared to free Cy3-
RNP or unencapsulated Cy3-RNP. d) CD spectra of free HypaRNP and HypaRNP-nanosome. Either buffer or the nanosome was used as a baseline 
signal for the RNP or RNP-nanosome, respectively. e) Small-angle X-ray scattering measurements in a globular fitting curve for HypaRNP, nanosome, 
and HypaRNP-nanosome. f) Pair distribution function derived from SAXS measurements of HypaRNP, C8dNP2 nanosome, and HypaRNP-nanosome.
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scattering as a standard. The RNP-nanosome showed a mass 
increase of 339 kDa compared to nanosome only, suggesting 
that each nanosome may contain ≈2 RNP molecules (Table S4 
(Supporting Information) and Figure 1c).
We sought to access the nanosome-mediated intracellular 
delivery of HypaRNP. To the end, we generated eGFP-reporter 
HEK cells, which harbored an eGFP gene integrated into the 
host genome. We harvested the eGFP-reporter HEK cells, 
which stably express the eGFP protein using flow cytometry 
(Figure S6, Supporting Information). The cytotoxicity of our 
delivery system was then examined based on the measurement 
of cell viability. We found no significant toxicity below 50 × 10−6 m 
concentration of the C8dNP2-based nanosome (Figure S7a–c, 
Supporting Information). Cell viability was reduced by ≈20−70% 
in the concentration range of 50–100 × 10−6 m (Figure S7a–c, 
Supporting Information). Consistently, the cellular mor-
phology was not influenced by the treatment with 0.5 × 10−6 m  
of HypaRNP-unencapsulated or encapsulated nanosome 
Figure 3. Intracellular delivery of the Cy3-HypaCas9 RNP complex in human embryonic kidney cells via C8dNP2-based nanosomes. a) Cellular mor-
phology was probed by filamentous actin (red). Time tracking of cellular uptake of b) encapsulated and c) unencapsulated HypaRNP-nanosomes. Cy3-
labled HypaRNP was used to probe the HypaRNP delivery. d) Percentage of intracellular delivery of the HypaRNP mediated by the nanosomes. Zero 
represents the beginning of the treatment. e) Relative percentage of nuclear localization of HypaRNP. Representative confocal z-stacking 3D images 
show the location of HypaRNP within the nucleus. Scale bar, 20 µm.
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(25 × 10−6 m) compared to untreated cell population (Figure 3a). 
We anticipated that highly efficient gene editing would be 
achieved by effective RNP delivery. To assess the efficiency of 
delivering HypaRNP by the C8dNP2-based nanosomes, we 
treated eGFP-reporter HEK cells in Dulbecco’s modified Eagle’s 
medium with our HypaRNP-nanosome system. The efficiency 
of cellular uptake of Cy3-HypaRNP was probed through Cy3 
fluorescence. The cellular uptake and release of HypaRNP 
were shown to increase from 30 min post-treatment, and the 
process was nearly complete at 4 h with 70 ± 11% efficiency. 
The Cy3 fluorescence was then cleared in the cells at 24 h. 
On the other hand, the fluorescence was not observed in cells 
treated with either free HypaRNP or unencapsulated Cy3-
HypaRNP (Figure 3b–d and Figure S8, Supporting Informa-
tion). Importantly, we observed that RNP also rapidly reached 
cell nuclei after transcytosis (Figure S8, Supporting Informa-
tion). To validate the nuclear localization of the RNP, we per-
formed Z-stacking to construct a 3D image of the nuclei at 
4 h post-treatment. Our 3D images and Z-axis sections revealed 
that the Cy3-HypaRNP is specifically localized in most nuclei 
treated with the RNP-nanosomes (58 ± 13%), while unencap-
sulated Cy3-HypaRNP showed nonspecific spatial distribution 
(Figure 3e and Figure S9, Supporting Information).
To subsequently investigate the nanosome-based delivery 
system could efficiently mediate genome modification in 
the human cells; we targeted the endogenous eGFP gene in 
our eGFP-reporter HEK cell system (Figure 1c). Delivery of 
CRIPSR/Cas9 system to nucleus induces double-strand breaks 
(DSB) at the target genomic loci at the eGFP gene, and the 
repair of the DSB by cellular system results in insertion/dele-
tion (indels) mutations at the DNA cleavage point, which may 
abrogate the expression of the reporter eGFP.[16] The HEK cells 
were treated twice sequentially with either unencapsulated 
HypaRNP or HypaRNP-encapsulated nanosomes, and subse-
quently incubated for 3 days. The eGFP fluorescence was then 
analyzed using either confocal microscopy or flow cytometry. We 
observed that the unencapsulated and encapsulated HypaRNP-
nanosome treatment reduced the eGFP expression by 7 ± 5% 
and 37 ± 18%, respectively, compared to the untreated control 
(Figure 4a and Figure S10a, Supporting Information). Further 
flow cytometry analysis showed that the average frequency of 
eGFP-negative cells in the population was 17.2 ± 2.6% for the 
nanosome-mediated treatment with reference to untreated cells 
(Figure 4b,c and Figure S10b, Supporting Information). Mean-
while, the treatment with unencapsulated HypaRNP resulted 
in slight and nonsignificant increase of the eGFP-negative 
population, suggesting the importance of nanosome-mediated 
HypaRNP delivery. The flow cytometry data also revealed the 
frequency of disruption of the eGFP gene modification by 
the nanosome-mediated methods was higher compared to 
that obtained using lipofectamine 2000 (9.1 ± 1.5%) or CRIS-
PRMAX (11.4 ± 1.8%) (Figure 4c and Figure S10b, Supporting 
Information). To further access the target gene modification 
rate, we isolated genomic DNA and PCR amplified the eGFP 
genomic locus using specific set of primers (Table S1, Sup-
porting Information). The amplified PCR product was treated 
with mismatch-sensitive T7 endonuclease 1 (T7E1). Results 
of the T7E1 assay showed an indel mutation frequency up to 
27.6% (Figure 4d) that is slightly higher than that of SpCas9WT 
(26.1%) (Figure S10c, Supporting Information). The gene 
editing of the HypaRNP-encapsulated nansomes was further 
validated in eGFP-reporter human glioblastoma cells with 
≈20% of indel mutation frequency (Figure S11 (Supporting 
Information) and Figure 4e). The frequency level achieved by 
lipopeptide-based nanosome-mediated delivery is significantly 
higher compared to previous systems such as SpCas9WT-conju-
gated poly-arginine (≈6%),[17] plasmid encoding SpCas9WT and 
sgRNA (≈7%),[18] gold nanoparticle (≈11%);[6] and comparable 
to delivery platforms of black phosphorus nanosheets (≈32%)[8] 
or Zeolitic Imidazolate frameworks (≈30%).[9] Collectively, our 
data showed that the HypaRNP-delivered nanosomes efficiently 
mediated editing of the endogenous gene in human cells.
In conclusion, we successfully generated and characterized 
a C8dNP2 lipopeptide-based nanosome system that efficiently 
delivered hyperaccurate SpCas9 RNP complex into human cells. 
Our system showed high efficiency (70 ± 11%) of intracellular 
delivery in HEK cells at 4 h post-treatment. Further analysis 
showed the HypaRNP-induced endogenous eGFP gene editing 
frequency of indel mutations were up to 27.6% in HEK and 
19.7% in human glioblastoma cells. Together, we conclude that 
the lipopeptid-based nanosome-mediated system efficiently deliv-
ered HypaRNP for endogenous editing, which will contribute to 
broaden the scope for transient gene editing technology.
Experimental Section
Lipopeptide Synthesis, Purification, and Characterization: Peptides 
were synthesized using Fmoc-solid-phase-peptide-synthesis (SPPS) on 
a Libertyblue automatic microwave synthesized system. The mixture 
of 5:4.9:10:1 molar ratio of amino acid: N,N-diisopropylcarbodiimide 
(DIC): ethyl 2-cyano-2-(hydroxyimino)acetate (Oxyma): resin was used 
for each coupling reaction. To generate the lipopeptide, aliphatic chains 
were conjugated to peptides by coupling of octanoic acid (8C), decanoic 
acid (10C), or myristic acid (14C) to the N-terminus of the peptide. 
The Fmoc deprotection reaction was performed using piperidine: 
dimethylformamide (DMF) (ratio 20:80 v/v). The products finally were 
cleaved from the resin using a mixture of trifluoroacetic acid (TFA), 
triisopropylsilane (TIS), and deionized water (DI water) (95:2.5:2.5 v/v) 
for 2 h at ambient temperature, and subsequently precipitated using 
cold anhydrous diethyl ether. The products were loaded on C4 column 
(Waters XBridgeTM, Massachusetts, USA) and purified using reverse-
phase HPLC (Waters Quaternary Gradient Module 2545) and gradients 
of mobile phase A (0.1% TFA solution) and mobile phase B (90% of 
solution of 0.1% TFA in ACN (Acetonitrile)). The purity and molecular 
mass of the fractions were subsequently confirmed using MALDI-TOF 
mass spectra with flex control 1.01 (Brucker Ultraflex III, Germany).
Preparation of HypaRNP-Encapsulated Nanosome: For lipopeptide-
based nanosome formation, the working molarity was determined 
by screening different concentrations. For generating the HypaRNP-
encapsulated nanosome, the lyophilized lipopeptide was dissolved in 
PBS buffer, pH 7.4, supplemented with 5 × 10−3 m MgCl2, 10% glycerol, 
and 0.2 × 10−6 m saturated fatty acid. The RNP-encapsulated nanosome 
was prepared by sonication with 20% amplitude for 15 min, pulse/pause 
of 2 s/2 s at 4 °C (Sonics, UK), simultaneously added HypaRNP. The 
solution was subsequently filtered through 0.2 × 10−6 m Whatman filter 
membrane (Merck, MA, USA) and immediately used for treatment. 
The encapsulation efficiency was monitored based on the absorbance 
spectra of the Cy3-labled Cas9 per the following formula: efficiency (%) = 
[(unencapsulated − encapsulated)/unencapsulated Cy3HypaRNP] × 100. 
The spectra were measured using UV–visible spectroscopy (Cary 8454 
UV-Vis, Aglient Technologies, CA, USA)
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Solution SAXS Measurements: SAXS measurements were performed 
at Pohang Accelerator Laboratory, 4C SAXS II beamline (BL4C, PAL, 
Korea). A light source from an In-vacuum Undulator 20 (IVU20: 1.4 m 
short, 20 mm period) of the Pohang Light Source II storage ring yielded 
an X-ray beam wavelength of 0.73 Å. The magnitude of scattering 
vector, q = (4π/λ) sin θ, was 0.070 nm−1 < q < 1.2 nm−1, where 2θ is the 
scattering angle and λ is X-ray beam the wavelength. X-ray diffraction 
data were collected in capillary cells, at 4 °C, with 4.0 m of sample-
to-detector distance. SAXS patterns were collected for six successive 
frames of 5 s exposure to monitor radiation damage. Final scattering 
data were generated by subtracting with control and merging data from 
all concentrations. The pair distribution function P(r) was calculated 
using the Fourier inversion of the scattering intensity I(q). The molecular 
masses of samples were determined using BSA scattering as a standard. 
Detailed SAXS data and analysis statistics are summarized in Table S4 
(Supporting Information).
Target DNA Cleavage and Indel Mutation Assay: The DNA duplex 
substrate was amplified and purified from the PCR product of eGFP 
gene. The Cas9:sgRNA RNP complex was purified using a size exclusion 
column. Reaction was conducted by mixing the DNA substrate and RNP 
(ratio 1:10) in buffer C (20 × 10−3 m Hepes-NaOH, pH 7.4, 150 × 10−3 m 
NaCl, 5 × 10−3 m MgCl2, 0.1 × 10−3 m EDTA, 5% glycerol, 5 µg mL−1 BSA) 
for 30 min at 37 °C. The reaction was quenched by adding proteinase 
K (1 mg mL−1) at room temperature for 20 min. The cleavage products 
were fractionated using 2% agarose gel electrophoresis. For analysis 
of indel mutation frequency, the T7E1 assay was performed. Genomic 
DNA from human cells was extracted using the genomic DNA isolation 
kit (Invitrogen, MA, USA). The eGFP gene was amplified from genomic 
DNA using Q5 fidelity DNA polymerase (NEB, MA, USA) and specific 
set of primers (Table S1, Supporting Information). After denaturation 
and annealing of the PCR product, the sample was digested with T7E1 
(Toolgen, Korea) for 20 min at 37 °C per manufacturer’s instructions. 
Figure 4. Nanosome-mediated delivery of HypaRNP induces endogenous gene modification. a) Lipopeptide-based nanosome-mediated intracellular 
delivery of HypaRNP targets eGFP gene modification, thus reducing eGFP protein expression. b) Schematic representation of the flow cytometric 
analysis of eGFP-negative cells containing RNP-induced indel mutations. c) The comparison of the frequency of eGFP-negative cell population cal-
culated from flow cytometry. The frequency of nanosome-mediated RNP delivery-induced indel mutations on the eGFP target gene in d) HEK and e) 
glioblastoma cells. Arrows indicate the HypaRNP-modified bands. Percentage of indel mutation was quantified using ImageLab. p-values compared to 
untreated control are denoted as * and ** for p ≤ 0.05 and p ≤ 0.01, respectively. Scale bar, 20 µm.
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The digestion product was separated and visualized using 2% agarose 
gel electrophoresis and staining with safe SYBR (Thermo Scientific, 
USA). Subsequently, the bands were quantified to obtain the gene 
modification frequencies mediated by the CRIPSR/Cas9 system using 
ImageLab (Chemidoc, Biorad, USA) per the following formula: frequency 
(%) = [1 − (cleaved fractions/total)] × 100. Experiments were conducted 
in triplicate. The primers used for amplification and the guide RNA 
sequence are shown in Table S1 (Supporting Information).
Supporting Information
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